Ajanta Pharma received an Establishment Inspection Report (EIR) for its manufacturing facility at Paithan, Maharashtra, from the United States Food and Drug Administration. According to the company's regulatory filing, the cGMP inspection was conducted from April 13, 2026, to April 21, 2026, and has been classified as Voluntary Action Indicated (VAI). The VAI classification is one of three possible outcomes assigned by the USFDA following a facility inspection, indicating that while the agency may have noted certain observations during the inspection process, no regulatory or administrative action is deemed necessary at this stage. On April 22, the firm had previously stated that the US FDA had concluded an inspection at the Paithan facility, which was closed with the issuance of Form 483 with five observations. The VAI status signifies that while minor observations were made, no regulatory action is required, ensuring continued product approvals and supply stability for the US market, which accounts for 24% of Ajanta's consolidated sales. The Paithan facility's adherence to current Good Manufacturing Practices (cGMP) was the focus of the inspection, with the EIR serving as confirmation of the facility's compliance with USFDA standards.
The drug firm reported robust financial results for the fourth quarter ended March 31, 2026. Net profit increased 18.4% year-on-year to ₹266.7 crore compared with ₹225.3 crore in the previous year period. Revenue jumped 21.5% to ₹1,421.6 crore as against ₹1,170.4 crore in the same quarter of the previous fiscal year. EBITDA rose 12.2% to ₹333.4 crore in the reporting quarter, contrasting with ₹297.2 crore in the corresponding period last year. However, EBITDA margin stood at 23.5% for the quarter, compared with 25.4% in the same period last year. In May 2026, Ajanta Pharma reported a 15% year-on-year increase in net profit for the previous fiscal year, driven by strong growth in the branded generic segments of India and Southeast Asia.
The USFDA's VAI classification for the Paithan unit is a 'clean chit' in practical terms for specialty pharma players like Ajanta. The clearance enables the company to continue its ANDA (Abbreviated New Drug Application) filing and approval pipeline from this site, with the USFDA now able to grant final approvals for pending ANDAs filed from the Paithan facility. This regulatory risk overhang for the Paithan facility is now completely removed, preventing any delays in new product launches in the US market where Ajanta focuses on high-margin, low-competition niche generics. The VAI status strengthens investor confidence in Ajanta Pharma's operational compliance standards and ensures capital allocation remains focused on R&D and market expansion rather than remedial capital expenditure. Receiving the EIR demonstrates the company's commitment to maintaining high manufacturing standards and its ability to meet the stringent requirements set by global regulatory bodies, likely bolstering its reputation and supporting business operations in international markets.
